Kura Oncology completes enrollment of 85 patients in Phase 2 KOMET-001 trial; topline data expected early 2025

Kura Oncology, Inc.

Final enrollment of 85 patients in Phase 2 registration-directed trial of menin inhibitor ziftomenib for NPM1-mutant AML.
Topline data from KOMET-001 trial expected in early 2025.
Trial targets relapsed/refractory NPM1-mutant acute myeloid leukemia.

item 8.01

Kura Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-147030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.